相关实验视频

Updated: Jun 15, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

稳定的iRGD修改增强了NY-ESO-1 TCR-T透到固体瘤中的作用,并与PD-1阻塞协同作用

Yirong Wu¹, Lanqun Qin², Jiayu Wang³

¹Department of the Comprehensive Cancer Center, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, 321 Zhongshan Road, Nanjing, 210008, China.

Cancer immunology, immunotherapy : CII

|May 30, 2025

概括

这项研究通过改善T细胞透和克服免疫抑制来增强固体瘤的T细胞受体修饰T细胞 (TCR-T) 治疗. 将iRGD修饰的TCR-T细胞与PD-1阻断相结合,为治疗耐火性瘤提供了一个新的策略.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
细胞疗法细胞疗法

背景情况:

固体瘤对T细胞受体改性T细胞 (TCR-T) 治疗具有挑战性,原因是T细胞透不良和免疫抑制瘤微环境.
现有的TCR-T疗法难以有效地准和透固体瘤组织,限制了它们的临床应用.

研究的目的:

使用iRGD修饰增强NY-ESO-1-特异性TCR-T细胞的瘤向和透能力.
研究iRGD修饰的NY-ESO-1 TCR-T细胞与PD-1阻断结合的协同效应,用于治疗固体瘤.

主要方法:

用NY-ESO-1-特异性T细胞受体修饰的T细胞 (TCR-T) 通过使用聚乙烯糖醇-脂 (PEG-脂质) 构建并稳定修饰非RGD.
对iRGD修饰的NY-ESO-1 TCR-T细胞进行了评估,以确定它们在体内准并透固体瘤组织的能力.
对iRGD修饰的NY-ESO-1 TCR-T细胞和PD-1阻断的联合治疗进行了评估,以确定其抗瘤疗效.

主要成果:

用iRGD稳定修改NY-ESO-1 TCR-T细胞被证明是提高T细胞透到固体瘤的有效策略.
经iRGD修改的NY-ESO-1 TCR-T细胞和PD-1阻断的组合在缓解免疫抑制信号方面显示出有希望的结果.
这种综合方法为克服NY-ESO-1-阳性固体瘤治疗耐药性的新协同策略提供了新的解决方案.

结论:

iRGD修饰是一种简单有效的方法,可以改善TCR-T细胞的向和透到固体瘤中.
用iRGD修改的NY-ESO-1 TCR-T细胞与PD-1阻断的组合代表了耐火性NY-ESO-1-阳性固体瘤的强有力的治疗策略.
这种方法有可能推动癌症免疫疗法用于固体瘤治疗.

关键词:

纽约-ESO-1 时间表在PD-1封锁中.固体瘤是一种固体瘤.这是一种TCR-T疗法.iRGDD 是一个很好的方法.

更多相关视频

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.